Sign In

Claudio Sustmann

Senior Leader, Antibody Discovery & External Innovation, Therapeutic Modalities, Roche

Claudio Sustmann is a senior scientist and leader in the field of antibody discovery and innovation at Roche, a major pharmaceutical company. Based on the available information, here's a profile of Claudio Sustmann:

Professional Background

Claudio Sustmann currently holds the position of Senior Leader in Antibody Discovery & External Innovation within the Large Molecule Research department at Roche.23 This role places him at the forefront of developing new therapeutic antibodies and exploring innovative approaches in the field of large molecule research.

Education and Expertise

Sustmann has a strong academic background in science:

  • He received his education at the Max Planck Institute of Immunobiology and Epigenetics2, which is renowned for its research in immunology and epigenetics.
  • His educational background includes degrees in Diplomarbeit and Vordiplom Chemie, indicating a solid foundation in chemistry and related sciences.

Research Contributions

Sustmann has made significant contributions to the field of antibody research and development:

  • He has been involved in pioneering work on bispecific antibodies, which are innovative therapeutic molecules capable of binding to two different targets simultaneously.1
  • Sustmann co-authored a paper on the quantification of cell surface proteins using bispecific antibodies, published in the journal Protein Engineering, Design and Selection.1
  • He has also contributed to research on novel antibody formats, such as the DuoMab, which is designed to enhance antibody-dependent cell-mediated cytotoxicity.4

Career at Roche

Sustmann has been with Roche for a considerable part of his career, where he has taken on leadership roles in antibody discovery and innovation.23 His work at Roche involves:

  • Leading efforts in antibody discovery and external innovation
  • Collaborating with other researchers and teams to develop new therapeutic approaches
  • Potentially overseeing partnerships and external collaborations in the field of antibody research

Claudio Sustmann's expertise and leadership in antibody discovery and innovation make him a key figure in Roche's efforts to develop new and improved therapeutic antibodies for various medical applications.

Highlights

May 8 · linkedin

A shout out to #PEGS22, it was again an exceptional summit - so many new things learned, people met, conversations had - thank you, #PEGSBoston for hosting us.  We also tremendously enjoyed the opportunity to meet our South San Francisco colleagues Arvind Rajpal and his team from Genentech. PEGS offers a great opportunity to meet  in person, something we sorely missed over the last 2 years of the pandemic. We hope everyone returned home safely.   Antibody engineering is a key technology powering our drug development pipeline. Roche and Genentech have a long heritage in antibody engineering - read more about our work here https://bit.ly/3LvVHbm. We are always looking for talent to work with us - get in touch if this is also your passion.

Nov 23 · linkedin

Exciting Opportunity at the Roche Innovation Center Munich!

Related Questions

What are some of Claudio Sustmann's most notable contributions to antibody discovery?
How has Claudio Sustmann's work impacted the field of therapeutic modalities?
What is the significance of Claudio Sustmann's role in External Innovation at Roche?
Can you provide examples of Claudio Sustmann's innovations in antibody discovery?
What is the background of Claudio Sustmann's work at the Max-Planck-Institute of Immunobiology?
Claudio Sustmann
Claudio Sustmann, photo 1
Claudio Sustmann, photo 2
Add to my network

Location

Greater Munich Metropolitan Area